Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: So. Much. News.

Dec 23 2017

• By Michael Cipriano

Keeping Track Feature image

Related Content

Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched

Jun 25 2014

Keeping Track: Neurology And Pain Products Keep FDA Occupied

Aug 17 2015

Keeping Track: A Burst of CRLs and BTDs, A Busy Week Of Submissions And Another Approval For Soliris

Oct 30 2017

Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions

Oct 23 2017

Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'

Dec 19 2017

Keeping Track: A Lilly Breast Cancer Approval, A Couple Of CRLs, And A Plethora Of Priority Reviews

Oct 02 2017

Keeping Track: US FDA Clears Three Novel Agents Over Three Days – Bavencio, Symproic And Xadago

Mar 26 2017

Agile's Phase III Data For Twirla Patch Fall Flat, Raise Doubts On Approval

Jan 05 2017

Keeping Track: Approvals, A Burst Of Submissions, And Some Priority Reviews

Dec 16 2017

Basilea's Ceftobiprole Dubbed Qualified Infectious Disease Product

Aug 13 2015

Agile SEC filing reveals FDA rejection for Twirla contraceptive

Mar 19 2014

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Dec 19 2017

Response Rates Rule In CGRP Inhibitor Migraine Studies

Jun 12 2017

Santen eyes uveitis market with top-line sirolimus data

Apr 07 2014

Related Companies

Spark Therapeutics, Inc.

Agile Therapeutics, Inc.

Santen Pharmaceutical Co., Ltd.

Novartis AG

Pfizer Inc.

Merck KGaA

Pfizer Inc.

Bristol Myers Squibb Company

Genentech, Inc.

Basilea Pharmaceutica Ltd.

Johnson & Johnson

Corium Inc.

Teva Pharmaceutical Industries Ltd.

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window